Skip to main content

Table 3 Association of age, tumor localization, gender, KPS and MGMT promoter methylation status with survival (all patients, n = 17)

From: Chemotherapy for intracranial ependymoma in adults

Variable

Number of patients (events)

Median OS (months) (95 % CI)

p value (log-rank)

p value (cox regression)

Hazard Ratio (95 % CI)

Agea

     

  < 40 years

9 (5)

48 (28.5–67.5)

  

1

  ≥ 40 years

8 (4)

41 (13.8–68.14)

0.587

0.589

1.45 (0.37–5.64)

Tumor localizationa

     

 Infratentorial

6 (0)

undefined

  

1

 Supratentorial

11 (9)

39 (9.87–68.13)

0.011 (*)

0.163

50.8 (0.20–12662.82)

Gender

     

 Female

3 (2)

41 (0–97.01)

  

1

 Male

14 (7)

48 (35.84–60.16)

0.888

0.888

0.89 (0.18–4.34)

KPSa

     

 100–80

11 (6)

48 (14.47–81.54)

  

1

  < 80

5 (3)

41 (11.96–70.04)

0.872

0.872

1.12 (0.28–4.52)

MGMT promoter methylation

     

 not methylated

9 (5)

40 (9.3–70.7)

  

1

 methylated

3 (2)

39 (undefined)

0.433

0.443

2.02 (0.34–12.2)

  1. CI confidence interval, KPS Karnofsky Performance Score, WHO World Health Organisation
  2. *, p < 0.05
  3. a, variables were determined at start of chemotherapy